Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue: 2020-2021

Historic Non-Current Deffered Revenue for Cullinan Therapeutics (CGEM) over the last 1 years, with Dec 2021 value amounting to $65,000.

  • Cullinan Therapeutics' Non-Current Deffered Revenue fell 12.16% to $65,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $65,000, marking a year-over-year decrease of 12.16%. This contributed to the annual value of $65,000 for FY2021, which is 12.16% down from last year.
  • Per Cullinan Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $65,000 for Q4 2021, which was down 2.99% from $67,000 recorded in Q3 2021.
  • Over the past 5 years, Cullinan Therapeutics' Non-Current Deffered Revenue peaked at $74,000 during Q4 2020, and registered a low of $65,000 during Q4 2021.
  • Its 2-year average for Non-Current Deffered Revenue is $69,800, with a median of $70,000 in 2021.
  • Data for Cullinan Therapeutics' Non-Current Deffered Revenue shows a maximum YoY decreased of 12.16% (in 2021) over the last 5 years.
  • Cullinan Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $74,000 in 2020, then declined by 12.16% to $65,000 in 2021.
  • Its last three reported values are $65,000 in Q4 2021, $67,000 for Q3 2021, and $70,000 during Q2 2021.